Survival outcomes after contralateral prophylactic mastectomy: A decision analysis

Journal of the National Cancer Institute

Volumn 106, Issue 8, 2014, Pages

  Portschy, Pamela R ^a   Kuntz, Karen M ^b   Tuttle, Todd M ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; BREAST CANCER; CANCER MORTALITY; CANCER SURVIVAL; CONTRALATERAL BREAST CANCER; CONTRALATERAL PROPHYLACTIC MASTECTOMY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LIFE EXPECTANCY; MASTECTOMY; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROBABILITY; PROPHYLACTIC SURGICAL PROCEDURE; REVIEW; SIMULATION; SURVIVAL TIME; TREATMENT OUTCOME; ADULT; ARTICLE; BREAST TUMOR; CANCER STAGING; DECISION SUPPORT SYSTEM; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; SECONDARY PREVENTION; UNITED STATES;

ADULT; BREAST NEOPLASMS; DECISION SUPPORT TECHNIQUES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIFE EXPECTANCY; MARKOV CHAINS; MASTECTOMY; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; SECONDARY PREVENTION; UNITED STATES;

EID: 84930707170     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju160     Document Type: Review

References (39)

1. King TA, Sakr R, Patil S, et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol. 2011;29(16):2158-2164.
2. McLaughlin CC, Lillquist PP, Edge SB. Surveillance of prophylactic mastectomy: trends in use from 1995 through 2005. Cancer. 2009;115(23):5404-5412.
3. Sorbero ME, Dick AW, Beckjord EB, et al. Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy. Ann Surg Oncol. 2009;16(6):1597-1605.
4. Tuttle TM, Habermann EB, Grund EH, et al. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol. 2007;25(33):5203-5209.
5. Yao K, Stewart AK, Winchester DJ, et al. Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998-2007. Ann Surg Oncol. 2010;17(10):2554-2562.
6. Güth U, Myrick ME, Viehl CT, et al. Increasing rates of contralateral prophylactic mastectomy-a trend made in USA? Eur J Surg Oncol. 2012;38(4):296-301.
7. Metcalfe KA, Lubinski J, Ghadirian P, et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol. 2008;26(7):1093-1097.
8. Han E, Johnson N, Glissmeyer M, et al. Increasing incidence of bilateral mastectomies: the patient perspective. Am J Surg. 2011;201(5):615-618.
9. Abbott A, Rueth N, Pappas-Varco S, et al. Perceptions of contralateral breast cancer: an overestimation of risk. Ann Surg Oncol. 2011;18(11):3129-3136.
10. Goldflam K, Hunt KK, Gershenwald JE, et al. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer. 2004;101(9):1977-1986.
11. Herrinton LJ, Barlow WE, Yu O, et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol. 2005;23(19):4275-4286.
12. McDonnell SK, Schaid DJ, Myers JL, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol. 2001;19(19):3938-3943.
13. Peralta EA, Ellenhorn JD, Wagman LD, et al. Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg. 2000;180(6):439-445.
14. van Sprundel TC, Schmidt MK, Rookus MA, et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer. 2005;93(3):287-292.
15. Bedrosian I, Hu CY, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst. 2010;102(6):401-409.
16. Boughey JC, Hoskin TL, Degnim AC, et al. Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol. 2010;17(10):2702-2709.
17. Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. 2010;2010(11):CD002748.
18. Brewster AM, Bedrosian I, Parker PA, et al. Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status. Cancer. 2012;118(22):5637-5643.
19. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13(4):322-338.
20. Arias E. United States life tables, 2008. Natl Vital Stat Rep. 2012;61(3):1-64.
21. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER). Public Use Data 1973-2009. http://www.seer.cancer.gov. Accessed April 16, 2012.
22. SEER, Stat Software Version 8.0.4. http://www.seer.cancer.gov/seerstat/. Accessed April 16, 2012.
23. Allred DC, Anderson SJ, Paik S, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol. 2012;30(12):1268-1273.
24. Arimidex TAoiCTG, Forbes JF, Cuzick J, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45-53.
25. Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135-1141.
26. Early Breast Cancer Trialists' Collaborative G, Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771-784.
27. Quan G, Pommier SJ, Pommier RF. Incidence and outcomes of contralateral breast cancers. Am J Surg. 2008;195(5):645-650.
28. de la Pena-Salcedo JA, Soto-Miranda MA, Lopez-Salguero JF. Prophylactic mastectomy: is it worth it? Aesthetic Plast Surg. 2012;36(1):140-148.
29. El-Tamer MB, Ward BM, Schifftner T, et al. Morbidity and mortality following breast cancer surgery in women: national benchmarks for standards of care. Ann Surg. 2007;245(5):665-671.
30. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233-1241.
31. Nichols HB, Berrington de Gonzalez A, Lacey JV Jr, et al. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol. 2011;29(12):1564-1569.
32. Early Breast Cancer Trialists' Collaborative Group, Clarke M, Coates AS, et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet. 2008;371(9606):29-40.
33. Chung A, Huynh K, Lawrence C, et al. Comparison of patient characteristics and outcomes of contralateral prophylactic mastectomy and unilateral total mastectomy in breast cancer patients. Ann Surg Oncol. 2012;19(8):2600-2606.
34. Arrington AK, Jarosek SL, Virnig BA, et al. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Ann Surg Oncol. 2009;16(10):2697-2704.
35. Stucky CC, Gray RJ, Wasif N, et al. Increase in contralateral prophylactic mastectomy: echoes of a bygone era? Surgical trends for unilateral breast cancer. Ann Surg Oncol. 2010;17(Suppl 3):330-337.
36. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22(12):2328-2335.
37. Cappelli M, Surh L, Humphreys L, et al. Measuring women's preferences for breast cancer treatments and BRCA1/BRCA2 testing. Qual Life Res. 2001;10(7):595-607.
38. Lidgren M, Wilking N, Jonsson B, et al. Health related quality of life in different states of breast cancer. Qual Life Res. 2007;16(6):1073-1081
39. Altschuler A, Nekhlyudov L, Rolnick SJ, et al. Positive, negative, and disparate - women's differing long-term psychosocial experiences of bilateral or contralateral prophylactic mastectomy. Breast J. 2008;14(1):25-32.